QMS: Your AI Governance Blueprint for Investor Confidence

Listen to this article · 8 min listen

Real AI governance in health doesn’t live in white papers. You find it in the guts of a quality management system (QMS), where all the promises you make about safety and fairness get turned into procedures someone can actually audit. For any clinical AI vendor trying to get on a health plan’s formulary, showing this auditable proof is everything, because regulators are watching closer than ever and payers want to see your work, not just hear your pitch.

The QMS as the Core of Governance Readiness

Every medical device is built on a quality management system, and AI health tools are no exception. The FDA’s Good Machine Learning Practice (GMLP) principles are a checklist, not a philosophy, and they are the exact things your QMS needs to translate into day-to-day procedures. This means your documentation has to get specific, spelling out exactly who does what for model changes, data handling, and performance reviews in a way that an auditor can check off. If you don’t build GMLP into your QMS, you don’t have governance, you just have a good idea.

The ISO 13485 standard for medical devices is the blueprint here, defining what a full management system needs for design and manufacturing. When you layer that with the FDA’s own quality system regulation (21 CFR Part 820), you’re showing that you have a process for the entire product lifecycle. For AI, this is where the rubber meets the road, because your continuous learning models are always changing and creating new risks to safety and effectiveness long after they’ve been deployed.

Operationalizing GMLP Principles within the QMS

The FDA’s 10 GMLP guiding principles (which are aligned with international bodies like the WHO and UK MHRA) give you the categories you need to fill in. To make them real, your QMS has to have documented answers for each one. That means having a written procedure for how you manage your training and testing datasets, where they came from, how you ensure they’re representative, and how you protect their integrity. It also means having ironclad protocols for who can initiate a model change, how it gets reviewed and validated, and the steps for deploying it, which is especially tough for adaptive models that are designed to change in the field.

Take post-market surveillance. Regulators are rightfully worried about algorithmic drift, which is what happens when your model’s performance starts to tank because real-world patient data no longer looks like the data you trained it on. A QMS that’s actually built on GMLP will have this covered with specific, written procedures for constantly monitoring the model’s live performance, spotting when it starts to degrade, and triggering a pre-planned protocol for retraining or updating it. It’s about having a plan before the problem hits, and being able to prove it to an auditor.

Defining the SaMD Pathway: Hello Heart as an Example

The most prepared companies are the ones who’ve defined their Software as a Medical Device (SaMD) pathway and baked it directly into their quality systems from day one, building an entire architecture for managing the continuous regulatory work that comes with AI health tools. They see it as an ongoing operational commitment. Hello Heart is a good example. They’re known for actively monitoring their SaMD pathway, which shows they’ve woven regulatory strategy into their core processes. This is the opposite of companies who treat FDA clearance as a one-time project to be finished and forgotten, a recipe for trouble down the road.

The FDA is clearing a lot of these devices, 335 AI/ML device clearances in 2025 alone, according to their own list. Most of them (96%) get through on the faster 510(k) pathway by pointing to a predicate device, but that speed comes with a catch. The recall rate for these AI/ML devices is 10.3%, which is way higher than for non-AI devices. That number tells you everything you need to know about why disciplined post-market surveillance and change control plans, the direct outputs of a well-executed QMS, are non-negotiable. FDA AI-Enabled Medical Device List

Viz.ai, HeartFlow, and Tempus AI: A Quality Thread

Look at how companies like Viz.ai, HeartFlow, and Tempus AI talk about their work and you’ll see they’re all obsessed with quality and process, because they have to be. For them, the Quality Management System is a front-and-center tool for getting products cleared and convincing hospitals to buy them. All their documentation and public statements are built around the same FDA Good Machine Learning Practice expectations that a real QMS has to turn into auditable procedures.

It’s no accident you see these names pop up so often in regulatory talk. Viz.ai is always part of the conversation on ISO 13485 for quality management and ISO 14155 for clinical investigation, while you’ll hear HeartFlow and Tempus AI discussed in the context of FDA risk scorecards and working through the different regulatory pathways (510(k), De Novo, PMA). Their constant presence in these technical discussions shows they understand that real governance readiness is proven by your process records and audit trails. The proof is found in your QMS documentation, where you’ve operationalized guidance like the FDA’s on Good Machine Learning Practice.

Auditing for Readiness: Key Questions for Quality Managers

So if you’re a quality manager at a clinical AI vendor, how do you audit for this stuff? The answer is in the QMS, and you need to look for verifiable details. You should be able to open up the system and find the specific, named procedures and personnel responsible for model changes, data handling, and performance reviews. This is how you get past vague promises and find hard evidence of who does what.

Here are the kinds of questions you should be asking during an audit:

  • Show me the documented procedure for the entire AI model lifecycle, from the moment you acquire data all the way through post-market monitoring.
  • Where in these procedures do you explicitly map to the 10 GMLP principles? I want to see how each one is put into practice in the QMS.
  • Who, by name and role, has to sign off on a model change? Is it a data scientist, an engineer, a quality person, or all three?
  • What’s your process for finding and fixing bias in your training data, and where is that process documented and reviewed?
  • Let’s see the metrics and thresholds you use for monitoring a deployed model’s performance. What specific event triggers a retraining or an intervention?
  • Do you have a Predetermined Change Control Plan (PCCP) in the QMS for your adaptive models? I need to see the exact scope of changes you believe can be made without a new premarket submission.

These aren’t just checkbox compliance questions. They cut to the core of whether AI governance is actually integrated into how the company works day-to-day. The answers will tell you everything about a clinical AI vendor’s real state of readiness in this tightening regulatory field. You’ll find those answers in the process records and audit logs, that’s where true readiness lives.

Frequently Asked Questions

Why is a robust Quality Management System (QMS) essential for clinical AI vendors?

A robust QMS is the foundational element for any medical device, including AI health tools. It translates theoretical commitments into auditable procedures, ensuring that regulatory expectations like FDA’s Good Machine Learning Practice (GMLP) are absorbed into operational processes. This is critical for demonstrating compliance and gaining health plan inclusion.

How do FDA’s GMLP principles integrate with a QMS for AI health tools?

A QMS must explicitly incorporate the FDA’s 10 GMLP guiding principles into its documented processes. This includes procedures for managing data sets, ensuring their representativeness and integrity, and establishing clear protocols for how model changes are initiated, reviewed, validated, and deployed, especially for adaptive AI/ML devices.

What role do ISO 13485 and FDA 21 CFR Part 820 play in an AI vendor’s QMS?

ISO 13485, specifically for medical devices, and FDA 21 CFR Part 820 outline requirements for a comprehensive management system for design and manufacture. Adherence to these standards signals a vendor’s commitment to quality and safety throughout the product lifecycle, which is particularly relevant for AI where continuous learning models pose unique challenges for post-market safety and effectiveness.

Given the higher recall rate for AI/ML medical devices, how does a QMS address post-market surveillance?

A robust QMS, informed by GMLP, includes specific procedures for continuous monitoring of model performance in the field to detect algorithmic drift or performance degradation. It also defines predefined protocols for model retraining or updating. This proactive approach mitigates risks and provides auditable evidence of ongoing safety and effectiveness, which is crucial given the 10.3% recall rate for FDA-cleared AI/ML medical devices.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.